Roche Holding AG (RHHBY)
| Previous Close | 41.20 |
| Open | 41.20 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 40.89 - 41.32 |
| 52 Week Range | 37.88 - 53.86 |
| Volume | |
| Avg. Volume | 2,140,485 |
| Market Cap | 274.107B |
| Beta (5Y Monthly) | 0.29 |
| PE Ratio (TTM) | 17.90 |
| EPS (TTM) | 2.30 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.24 (3.01%) |
| Ex-Dividend Date | Mar 17, 2022 |
| 1y Target Est | 46.25 |
- Zacks
Sarepta (SRPT) Q2 Earnings Miss, DMD Drugs' Sales Robust
Strong demand for Sarepta's (SRPT) DMD drugs boosts the top line in the second quarter. However, the wider-than-anticipated losses drive the stock down in after-market trading.
- Zacks
Blueprint Medicines' (BPMC) Q2 Earnings & Revenues Miss Mark
Blueprint Medicines' (BPMC) earnings and revenues fall shy of estimates for the second quarter of 2022. However, the stock is up.
- Business Wire
Genentech’s Subcutaneous Formulation of Tecentriq Demonstrates Positive Phase III Results
SOUTH SAN FRANCISCO, Calif., August 02, 2022--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq® (atezolizumab) met its co-primary endpoints. The study showed non-inferior levels of Tecentriq in the blood (pharmacokinetics), when injected subcutaneously, compared with intravenous (IV) infusion, in cancer immunotherapy-naïve patients with locally advanced or metastatic non-smal
